Dosage of Boiron in details
(1 capsule = 2 mg)
Patients should receive appropriate fluid and electrolyte replacement as needed.
Acute Diarrhea
AdultsThe recommended initial dose is 4 mg (two capsules) followed by 2 mg (one capsule) after each unformed stool. Daily dosage should not exceed 16 mg (eight capsules). Clinical improvement is usually observed within 48 hours.
Children
In children 2 to 5 years of age (20 kg or less), the non-prescription liquid formulation (Boiron for oral solution, 1 mg/5 mL) should be used; for ages 6 to 12, either Boiron capsules or Boiron for oral solution may be used. For children 2 to 12 years of age, the following schedule for capsules or liquid will usually fulfill initial dosage requirements:
Recommended First Day Dosage Schedule
Two to five years: 1 mg t.i.d. (3 mg daily dose) (13 to 20 kg)
Six to eight years: 2 mg b.i.d. (4 mg daily dose) (20 to 30 kg)
Eight to twelve years: 2 mg t.i.d. (6 mg daily dose) (greater than 30 kg)
Recommended Subsequent Daily Dosage
Following the first treatment day, it is recommended that subsequent Boiron doses (1 mg/10 kg body weight) be administered only after a loose stool. Total daily dosage should not exceed recommended dosages for the first day.
Chronic Diarrhea
ChildrenAlthough Boiron has been studied in a limited number of children with chronic diarrhea; the therapeutic dose for the treatment of chronic diarrhea in a pediatric population has not been established.
Adults
The recommended initial dose is 4 mg (two capsules) followed by 2 mg (one capsule) after each unformed stool until diarrhea is controlled, after which the dosage of Boiron capsules should be reduced to meet individual requirements. When the optimal daily dosage has been established, this amount may then be administered as a single dose or in divided doses.
The average daily maintenance dosage in clinical trials was 4 to 8 mg (two to four capsules). A dosage of 16 mg (eight capsules) was rarely exceeded. If clinical improvement is not observed after treatment with 16 mg per day for at least 10 days, symptoms are unlikely to be controlled by further administration. Boiron capsules administration may be continued if diarrhea cannot be adequately controlled with diet or specific treatment.
Children Under 2 Years
The use of Boiron in children under 2 years is not recommended. There have been rare reports of paralytic ileus associated with abdominal distention. Most of these reports occurred in the setting of acute dysentery, overdose, and with very young children less than two years of age.
Elderly
No formal pharmacokinetic studies were conducted in elderly subjects. However, there were no major differences reported in the drug disposition in elderly patients with diarrhea relative to young patients. No dosage adjustment is required for the elderly.
Renal Impairment
No pharmacokinetic data are available in patients with renal impairment. Since the metabolites and the unchanged drug are mainly excreted in the feces, no dosage adjustment is required for patients with renal impairment.
Hepatic Impairment
Although no pharmacokinetic data are available in patients with hepatic impairment, Boiron should be used with caution in such patients because of reduced first pass metabolism.
What other drugs will affect Boiron?
Tell your doctor about all other medicines you use, especially saquinavir (Invirase).
This list is not complete and other drugs may interact with Boiron. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
Boiron interactions
Nonclinical data have shown that Boiron is a P-glycoprotein substrate. Concomitant administration of Boiron (16 mg single dose) with a 600 mg single dose of either quinidine, or ritonavir, both of which are P-glycoprotein inhibitors, resulted in a 2- to 3- fold increase in Boiron plasma levels. Due to the potential for enhanced central effects when Boiron is coadministered with quinidine and with ritonavir, caution should be exercised when Boiron is administered at the recommended dosages (2 mg, up to 16 mg maximum daily dose) with P-glycoprotein inhibitors.
When a single 16-mg dose of Boiron is coadministered with a 600 mg single dose of saquinavir, Boiron decreased saquinavir exposure by 54%, which may be of clinical relevance due to reduction of therapeutic efficacy of saquinavir. The effect of saquinavir on Boiron is of less clinical significance. Therefore, when Boiron is given with saquinavir, the therapeutic efficacy of saquinavir should be closely monitored.
References
- FDA/SPL Indexing Data. "6X9OC3H4II: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).
- MeSH. "Antidiarrheals". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
- European Chemicals Agency - ECHA. "Loperamide: The information provided here is aggregated from the "Notified classification and labelling" from ECHA's C&L Inventory. ". https://echa.europa.eu/information-o... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Boiron are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Boiron. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported frequency of use
No survey data has been collected yetConsumer reported doses
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
